Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- MRKR
- Price
- 1.08
- Stock movement down
- -0.09 (-7.69%)
- Company name
- Marker Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 9.64M
- Ent value
- 4.10M
- Price/Sales
- 1.79
- Price/Book
- 1.29
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -52.24%
- 1 year return
- -75.68%
- 3 year return
- -33.67%
- 5 year return
- -43.88%
- 10 year return
- -26.29%
Last updated: 2025-04-17
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
MRKR does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.79 |
| Price to Book | 1.29 |
| EV to Sales | 0.76 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 8.92M |
| EPS (TTM) | -1.08 |
| FCF per share (TTM) | -0.96 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 5.40M |
| Gross profit (TTM) | 203.52K |
| Operating income (TTM) | -10.19M |
| Net income (TTM) | -9.63M |
| EPS (TTM) | -1.08 |
| EPS (1y forward) | -2.19 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 3.77% |
| Operating margin (TTM) | -188.94% |
| Profit margin (TTM) | -178.54% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 9.00M |
| Net receivables | 744.41K |
| Total current assets | 10.91M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 10.91M |
| Accounts payable | 2.56M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 3.46M |
| Total liabilities | 3.46M |
| Shareholder's equity | 7.45M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -8.57M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -8.57M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -129.32% |
| Return on Assets | -88.30% |
| Return on Invested Capital | -129.32% |
| Cash Return on Invested Capital | -115.10% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.16 |
| Daily high | 1.17 |
| Daily low | 1.06 |
| Daily Volume | 20K |
| All-time high | 778.80 |
| 1y analyst estimate | 19.00 |
| Beta | 1.49 |
| EPS (TTM) | -1.08 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 13 May 2025 |
Downside potential
Loading...
Downside potential data
| MRKR | S&P500 | |
| Current price drop from All-time high | -99.86% | -14.24% |
| Highest price drop | -99.91% | -56.47% |
| Date of highest drop | 31 Mar 2023 | 9 Mar 2009 |
| Avg drop from high | -92.49% | -11.07% |
| Avg time to new high | 749 days | 12 days |
| Max time to new high | 2990 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
9.64M
Marketcap category
Small-cap
Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Employees
8
Investor relations
-
SEC filings
CEO
Peter L. Hoang
Country
USA
City
Houston
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page